Hosted on MSN11d
Sanofi's 21-Valent Pneumococcal Vaccine Enters Phase III
Sanofi SNY and its partner SK bioscience announced that they have expanded their agreement to develop, license and ...
Too Old to Operate15d
Sex Differences in Pneumococcal Vaccine Effectiveness for PDRH
The following is a summary of “Evaluating Sex Differences in Pneumococcal Disease Burden and Vaccination Effectiveness in ...
FierceBiotech12d
Sanofi pays SK bioscience €50M as children's pneumococcal vaccine enters phase 3
Sanofi is handing SK bioscience 50 million euros ($52 million) as the longtime partners take their next-gen pneumococcal ...
Pharmabiz9d
Sanofi begins phase 3 program for pneumococcal conjugate vaccine (PCV21); expands agreement with SK bioscience
Sanofi and SK bioscience have entered into a new chapter of their collaboration in pneumococcal vaccines with an expanded agreement to develop, license and commercialize next-generation PCVs for both ...
Couriermail18d
‘Three-fold challenge’: Immunisation Foundation of Australia warns deadly Pneumococcal disease hits 20-year high
The dangerous pneumococcal disease can be fatal to babies and children. Picture: CDC Pediatrician and infectious disease researcher Professor Peter Richmond said declining rates of vaccination ...
Yahoo Finance12d
SK bioscience and Sanofi expand agreement for pneumococcal conjugate vaccines
SK bioscience and Sanofi have expanded their agreement to jointly develop pneumococcal conjugate vaccines (PCVs) targeting both paediatric and adult populations. This partnership extension ...